Pharmaceutical combination comprising co-administration of taxane and N-(1-cyclohexyl-2-{2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide or pharmaceutically acceptable salt(s) thereof

The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.

Saved in:
Bibliographic Details
Main Authors ZAWEL LEIGH, TRAN MARY ANN, JENSEN MICHAEL RUGAARD, WANG YOUZHEN, STRAUB CHRISTOPHER SEAN
Format Patent
LanguageEnglish
Published 09.12.2014
Subjects
AGRICULTURE
ANIMAL HUSBANDRY
BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES
CHEMISTRY
FISHING
FORESTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HUNTING
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEST REPELLANTS OR ATTRACTANTS
PLANT GROWTH REGULATORS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTSTHEREOF
TRAPPING
Online AccessGet full text

Cover

More Information
Summary:The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
Bibliography:Application Number: US201313761634